Features of the clinical course of anaplastic lymphoma in children. Clinical case
DOI:
https://doi.org/10.15574/SP.2023.136.116Keywords:
children, non-Hodgkin’s lymphomas, anaplastic large cell lymphomaAbstract
Anaplastic large cell lymphoma (ALCL) is a rare type of T-cell non-Hodgkin lymphoma with a characteristic primary localized, mainly extra-bone marrow tumor growth of lymphoid tissue, the clinical picture of which includes lesions of peripheral lymph nodes and extranodal organs, such as bones, skin, lungs, liver, muscles which tissues and bone marrow.
Purpose - to acquaint practicing doctors with the features of clinical manifestations, differential diagnosis and course of ALCL in children.
Features of the clinical course of ALCL in a child are described. The main diagnostic value of the anamnesis, clinical picture, laboratory, instrumental, immunohistochemical and microscopic research methods, in particular trepan biopsy of this tumor, is highlighted. Microscopic examination of the tissue trepanbioptate show that in half of the cells of the bone marrow, its normal structure is revealed, hematopoietic bone marrow is present with the preservation of all sprouts, with a slightly increased number of megakaryocytes. Half of the cells are filled with solid layers of sharply atypical lymphocyte-like cells with a moderate amount of eosinophilic cytoplasm, the nuclei of tumor cells are large, vesicular, with the formation of 1-2 basophilic nuclei. In the tumor cells there are figures of mitosis, including atypical ones. Single hematopoietic cells of various germs are found between these cells. The conducted immunohistochemical study of tumor cells show that they are positive for common leukocyte antigen (CD4), negative for common cytokeratins, S-100, myogenin, MuoD1, which indicates their hematopoietic origin. Upon further examination, the tumor cells were positive for CD 30, negative for CD3, CD20, CD 43, CD 68, CD11c, tdt, myeloperoxidase, CD 1a. Staining for CD246 reveals a granular cytoplasmic reaction in tumor cells. The histological pattern and immunophenotype of tumor cells correspond to ALCL.
The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
References
Aladily TN, Khader M, Bustami N, Bazzeh F. (2022, Dec). Anaplastic large cell lymphoma, ALK-positive in very young children: A long-term follow-up of two cases and a review of the literature. Malays J Pathol. 44(3): 517-521. PMID: 36591719.
Chen Z, Chai F, Xi Y, Zhang H, Xu Y, Zhang Z et al. (2022, Jan). Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma. J Cancer Res Clin Oncol. 148(1): 267-278. Epub 2021 Jun 16. https://doi.org/10.1007/s00432-021-03691-7; PMid:34131801
Fedorenko ZP. (2022). Cancer in Ukraine, 2020-2021. Bulletin of the National Cancer Registry of Ukraine No. 23. URL: ncru.inf.ua.
Kada A, Fukano R, Mori T, Kamei M, Tanaka F, Ueyama J et al. (2020, Feb). A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children. Acta Med Okayama. 74(1): 89-94. doi: 10.18926/AMO/57959. PMID: 32099255.
Mehreen A, Wali R, Riaz S. (2020, Jul). Clinical Features and Treatment Outcomes of Children with Anaplastic Large Cell Lymphoma. J Coll Physicians Surg Pak. 30(7): 749-753. https://doi.org/10.29271/jcpsp.2020.07.749; PMid:32811608
Mussolin L, Le Deley MC, Carraro E, Damm-Welk C, Attarbaschi A, Williams D et al. (2020, Sep 24). Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers (Basel). 12(10): 2747. https://doi.org/10.3390/cancers12102747; PMid:32987765 PMCid:PMC7598675
Patel A, Pushpam D, Sharma MC, Thulkar S, Bakhshi S. (2020, Jun 15). Predictors of Outcome in Pediatric Anaplastic Large Cell Lymphoma. Indian Pediatr. 57(6): 523-526. https://doi.org/10.1007/s13312-020-1849-z; PMid:32562396
Pearson ADJ, Barry E, Mossé YP, Ligas F, Bird N, de Rojas T et al. (2021, Nov). Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Eur J Cancer. 157: 198-213. Epub 2021 Sep 15. https://doi.org/10.1016/j.ejca.2021.08.022; PMid:34536944
Rigaud C, Knörr F, Brugières L, Woessmann W. (2023, Mar). Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. Best Pract Res Clin Haematol. 36(1): 101444. Epub 2023 Feb 2. https://doi.org/10.1016/j.beha.2023.101444; PMid:36907641
Shen D, Song H, Zhang J, Liao C, Wang Y, Fang M, Tang Y. (2022, Jan 1). Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series. J Pediatr Hematol Oncol. 44(1): e1-e4. https://doi.org/10.1097/MPH.0000000000002137; PMid:33661174
Wang W, He L, Wu R, Yao J, Ma H, Cheng X et al. (2023, Mar). Anaplastic lymphoma kinase positive histiocytosis presenting as hemocytopenia in an infant. Pediatr Blood Cancer. 70(3): e30010. Epub 2022 Oct 2. https://doi.org/10.1002/pbc.30010; PMid:36184781
Yu BH, Zhang Y, Xue T, Shui RH, Lu HF, Zhou XY et al. (2021, Jan 5). The clinicopathological relevance of uniform CD56 expression in anaplastic large cell lymphoma: a retrospective analysis of 18 cases. Diagn Pathol. 16(1): 1. https://doi.org/10.1186/s13000-020-01059-y; PMid:33402163 PMCid:PMC7786455
Zhang YT, Wang LZ, Chang J. (2022, Feb 15). Characteristics and Outcomes of Chinese Children With Advanced Stage Anaplastic Large Cell Lymphoma: A Single-Center Experience. Front Oncol. 12: 832752. https://doi.org/10.3389/fonc.2022.832752; PMid:35242715 PMCid:PMC8885804
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
